The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
September 1, 2021
The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary… Continue reading
August 13, 2021
Please click here for more information on filling prescriptions under the Emergency Order issued by Governor DeSantis Continue reading